Previous article
Carpal Tunnel Syndrome
Jun 2024
Next article
Avoiding Racist and Judgmental Clinical Documentation: Helping to Achieve Health Equity
FPIN's Clinical Inquiries
From the Family Practice Inquiries Network

Bempedoic Acid for the Prevention of Cardiovascular Disease

Anne Mounsey, MD,
Maniraj Jeyaraju, MD,
University of North Carolina, Chapel Hill, North Carolina

American Family Physician. 2024;109(6):573-574.

Author disclosure: No relevant financial relationships.

Address correspondence to Anne Mounsey, MD, at anne_mounsey@med.unc.edu. Reprints are not available from the authors.

Author disclosure: No relevant financial relationships.

  1. 1.Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131-140.
  2. 2.Cicero AFG, Fogacci F, Hernandez AV, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group and the International Lipid Expert Panel. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121.
  3. 3.Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593-603.
  4. 4.Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195-203.
  5. 5.National Institute for Health and Care Excellence. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. April 28, 2021. Accessed December 5, 2023. https://www.nice.org.uk/guidance/ta694/chapter/2-Information-about-bempedoic-acid
  6. 6.Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel. Prog Cardiovasc Dis. 2023;79:2-11.

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (https://www.cebm.net).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to https://www.fpin.org or email questions@fpin.org.

Copyright © Family Physicians Inquiries Network. Used with permission.

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Clinical Inquiries published in AFP is available at https://www.aafp.org/afp/fpin.

Previous article
Carpal Tunnel Syndrome
Jun 2024
Next article
Avoiding Racist and Judgmental Clinical Documentation: Helping to Achieve Health Equity

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.